Computational nuclear oncology toward precision #RPTherapy: Current tools, techniques, & uncharted territories. ow.ly/7rGQ50VuMcT

An interesting read: Self-citation among highly cited #NuclearMedicine and #MedicalImaging researchers. ow.ly/wQPp50VuM9s

HER2 PET imaging can detect HER2-low and HER2-positive lesions in metastatic #BreastCancer patients, allowing for better select patients for T-DXd and other HER2-targeted therapies. ow.ly/utFq50VSPz4 #NuclearMedicine

Are FAP theranostics really happening? Will radiochemistry or biology win? doi.org/10.2967/jnum... #NuclearMedicine #Theranostics #RPTherapy

Theranostics for neuroblastoma: Making molecular radiotherapy work better. ow.ly/sHTA50VuLYN #NuclearMedicine #Theranostics #RPTherapy #Neuroblastoma

⁶⁸Ga-RAYZ-8009: A peptide PET tracer for targeting HCC in humans. ow.ly/wHQR50VEW0I #NuclearMedicine #PETscan #HCC

⁶⁸Ga-NeoB PET/CT has diagnostic potential in the staging of ER/PR-positive and HER2-negative breast cancer. Learn more: ow.ly/NJVA50VuLRT #NuclearMedicine #BreastCancer #PETscan

Consensus nomenclature for radionuclide therapy: Initial recommendations from Nuclear Medicine Global Initiative. ow.ly/2vT650VuLNW #NuclearMedicine #RPTherapy

Despite the superior performance of Choi criteria and other criteria, RECIST 1.1 guidelines are recommended for #NeuroendocrineTumor response assessment under radiopharmaceutical therapy. ow.ly/77t850VuLGS #NuclearMedicine

Is ²¹¹At really happening? ow.ly/vqIT50VuLFS #NuclearMedicine #RPTherapy